PTH134 + Placebo + Forsteo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Post-menopausal Osteoporosis
Conditions
Post-menopausal Osteoporosis
Trial Timeline
Sep 1, 2010 → —
NCT ID
NCT01224717About PTH134 + Placebo + Forsteo
PTH134 + Placebo + Forsteo is a phase 1 stage product being developed by Novartis for Post-menopausal Osteoporosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01224717. Target conditions include Post-menopausal Osteoporosis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01224717 | Phase 1 | Completed |
Competing Products
19 competing products in Post-menopausal Osteoporosis